Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Ruth Wester; Sonja Zweegman; Bronno van der Holt; Marie José Kersten; Edo Vellenga; Marinus van Marwijk-Kooy; Emelie Asselbergs; Okke de Weerdt; Monique C. Minnema; Sarah Lonergan; Antonio Palumbo; Annemiek Broijl; Pieter Sonneveld

doi:https://doi.org/10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Ruth Wester, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Emelie Asselbergs, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	e370
Journal	HemaSphere
Volume	4
Issue number	4
DOIs	https://doi.org/10.1097/HS9.0000000000000370
Publication status	Published - 2020

Access to Document

https://doi.org/10.1097/HS9.0000000000000370

Cite this

Wester, R., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M. C., Lonergan, S., Palumbo, A., Broijl, A., & Sonneveld, P. (2020). Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 4(4), Article e370. https://doi.org/10.1097/HS9.0000000000000370

@article{f214e79bf39b4a53bb7aa7ab06c58acd,

title = "Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial",

author = "Ruth Wester and Sonja Zweegman and {van der Holt}, Bronno and Kersten, {Marie Jos{\'e}} and Edo Vellenga and {van Marwijk-Kooy}, Marinus and Emelie Asselbergs and {de Weerdt}, Okke and Minnema, {Monique C.} and Sarah Lonergan and Antonio Palumbo and Annemiek Broijl and Pieter Sonneveld",

year = "2020",

doi = "https://doi.org/10.1097/HS9.0000000000000370",

language = "English",

volume = "4",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "4",

}

Wester, R, Zweegman, S, van der Holt, B, Kersten, MJ, Vellenga, E, van Marwijk-Kooy, M, Asselbergs, E, de Weerdt, O, Minnema, MC, Lonergan, S, Palumbo, A, Broijl, A & Sonneveld, P 2020, 'Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial', HemaSphere, vol. 4, no. 4, e370. https://doi.org/10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. / Wester, Ruth; Zweegman, Sonja; van der Holt, Bronno et al.
In: HemaSphere, Vol. 4, No. 4, e370, 2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma

T2 - 8 vs 4 Induction Cycles; the Carthadex Trial

AU - Wester, Ruth

AU - Zweegman, Sonja

AU - van der Holt, Bronno

AU - Kersten, Marie José

AU - Vellenga, Edo

AU - van Marwijk-Kooy, Marinus

AU - Asselbergs, Emelie

AU - de Weerdt, Okke

AU - Minnema, Monique C.

AU - Lonergan, Sarah

AU - Palumbo, Antonio

AU - Broijl, Annemiek

AU - Sonneveld, Pieter

PY - 2020

Y1 - 2020

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148297111&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/32885140

U2 - https://doi.org/10.1097/HS9.0000000000000370

DO - https://doi.org/10.1097/HS9.0000000000000370

M3 - Article

C2 - 32885140

SN - 2572-9241

VL - 4

JO - HemaSphere

JF - HemaSphere

IS - 4

M1 - e370

ER -

Wester R, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M et al. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere. 2020;4(4):e370. doi: https://doi.org/10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Access to Document

Other files and links

Cite this